Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay® (odevixibat) in Alagille Syndrome

Stock Information for Albireo Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Albireo Pharma Inc.

ALBO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Albireo Pharma, Inc. Is Fair to Shareholders
Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directors
Albireo to Participate in Jefferies London Healthcare Conference
Albireo Reports Q3 2022 Financial Results and Business Update
Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC Types
Albireo Announces 2022 SPARK Grant Winners

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.